Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Galderma

< Previous 1 2 3 Next >

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch

May 22, 2026

From Galderma

Via Business Wire

Galderma Launches New Alastin Regenerating Skin Nectar with TriHex+™, Powered by Its Next-Generation TriHex Technology® Regenerative Platform

April 16, 2026

From Galderma

Via Business Wire

Interim Data From Two Ongoing Investigator-initiated Trials Highlight the Role of Sculptra® and Restylane® in Addressing Aesthetic Changes Associated With Weight Loss Medications and Menopause

April 09, 2026

From Galderma

Via Business Wire

Galderma Debuts ALASTIN Signature Practices in Partnership With Leading Aesthetic Practices to Elevate Regenerative, Peri-Procedural Skincare

April 07, 2026

From Galderma

Via Business Wire

AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs

March 24, 2026

From Galderma

Via Business Wire

Galderma Receives U.S. FDA Approval for Restylane® Contour™ for the Correction of Temple Hollowing

March 23, 2026

From Galderma

Via Business Wire

Galderma Publishes Invitation and Agenda for Its 2026 Annual General Meeting

March 20, 2026

From Galderma

Via Business Wire

AMWC 2026: Galderma Showcases Category‑leading Innovation With a Comprehensive Portfolio and Holistic, Future‑focused Aesthetic Strategies

March 17, 2026

From Galderma

Via Business Wire

Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering

March 11, 2026

From Galderma

Via Business Wire

Galderma Introduces Cetaphil AM/PM Antioxidant Serums, a New Science-Driven Defense and Recovery System for Sensitive Skin

March 09, 2026

From Galderma

Via Business Wire

Galderma’s Nemluvio® (nemolizumab) Demonstrates Long-Term Disease Control in Prurigo Nodularis up to Three Years

February 27, 2026

From Galderma

Via Business Wire

Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics

February 25, 2026

From Galderma

Via Business Wire

Galderma Announces Appointment of New Chief Financial Officer

February 16, 2026

From Galderma

Via Business Wire

We Are All Sculptra: First-of-its-Kind Galderma Initiative to Demonstrate How Everyone Can Benefit from Sculptra’s Regenerative Properties

February 12, 2026

From Galderma

Via Business Wire

Galderma Expands Restylane® Portfolio in Japan With Launch of OBT™ Hyaluronic Acid Injectables Restylane Defyne™ and Refyne™

February 11, 2026

From Galderma

Via Business Wire

Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission

February 02, 2026

From Galderma

Via Business Wire

Galderma Tackles Menopause-related Skin Changes With Global Survey and Clinical Trial Inclusivity

January 30, 2026

From Galderma

Via Business Wire

Galderma Unveils ‘Wake Up To Restylane’, Underscoring Restylane as the Ideal Hyaluronic Acid Treatment for Always-On Natural Beauty

January 29, 2026

From Galderma

Via Business Wire

IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry’s Broadest Injectable Aesthetics Portfolio

January 22, 2026

From Galderma

Via Business Wire

Galderma Provides Update on Arbitration Case Regarding Neuromodulator Research and Development Partnership

January 21, 2026

From Galderma

Via Business Wire

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics

January 14, 2026

From Galderma

Via Business Wire

New Published Data Confirms Nemluvio® (Nemolizumab) Can Rapidly Relieve Itch and Improve Sleep in as Early as Two Days in Both Atopic Dermatitis and Prurigo Nodularis

December 17, 2025

From Galderma

Via Business Wire

Galderma Announces First Patient Enrollment in Study to Assess Nemolizumab in Adults With Chronic Pruritus of Unknown Origin

December 11, 2025

From Galderma

Via Business Wire

Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body

December 05, 2025

From Galderma

Via Business Wire

Galderma Secures ‘BBB’ Credit Rating With Positive Outlook from S&P Global Ratings

December 04, 2025

From Galderma

Via Business Wire

ASDS 2025: Compelling New Data on Restylane, Sculptra and Relfydess Highlight Galderma’s Innovative Injectable Aesthetics Portfolio and Pipeline

November 17, 2025

From Galderma

Via Business Wire

AMWC Dubai: Galderma Demonstrates Injectable Aesthetics Leadership Through Updates on Its Scientific Innovations and Community Education

September 24, 2025

From Galderma

Via Business Wire

Galderma Launches Transformative Skincare Segment With Cetaphil’s New Skin Activator Hydrating & Firming Line, in Partnership With Actor and Filmmaker Mariska Hargitay

September 18, 2025

From Galderma

Via Business Wire

EADV 2025: Galderma Reinforces Leadership in Dermatology With Latest Advances in Sensitive Skin and Itch

September 11, 2025

From Galderma

Via Business Wire

Galderma Launches Alastin® in China, Supporting the Skin’s Natural Regenerative Abilities in a Rapidly Expanding Market

September 10, 2025

From Galderma

Via Business Wire

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.